Search

Cardiometabolic diseases are a group of metabolic dysfunctions mainly characterized by insulin resistance, impaired glucose tolerance, dyslipidemia, hypertension, and central adiposity that are major contributors to increased risk of acute vascular events such as myocardial infarction, heart failure and stroke. Cardiometabolic Diseases: Molecular Basis, Early Detection of Risks, and Management provides detailed information on all aspects of metabolic dysfunctions and associated risks for cardiometabolic diseases, including a thoughtful discussion of cellular and molecular mechanisms involved in the progression of metabolic risks, the approaches for the early detection and robust management of metabolic risks. Written by a team of expert contributors, this book is useful reading for researchers and clinicians interested on recent advances in etiology of cardiometabolic diseases, the latest noninvasive approaches for diagnosis, risk assessment tools, therapeutic strategies, and also aspects of prevention of cardiometabolic diseases. - Covers all aspects of cardiometabolic diseases, from cellular and molecular mechanisms involved in the development of metabolic risks to clinical practice - Provides established guidelines that facilitate effective management of the independent risk factors that promote vascular diseases - Discusses the use of diagnostic tools to empower patients to self-monitor the progress or regress of modifiable risks

This book reviews, in one place, the breadth of articles that form the basis for the current practice of medicine. When physicians examine medical literature, there are articles that are quoted over and over again, as well as articles that have established the standards that are so embedded that we no longer think of where those standards came from. When clinicians treat patients with diabetes, why do we aim for an A1c less than 7%? That standard comes primarily from two trials, the DPPT and the UKPDS trial, both of which broke new ground when they were published. In addition, the ACCORD trial informed us that a lower A1c goal does not improve outcomes, and may in fact lead to worse outcomes. Understanding these trials helps physicians to make better decisions for their patients and gives them a greater appreciation for the information they work with every day.The chapters are organized by system such as respiratory, cardiovascular, diabetes, etc. and within each system,in the chronological order of publication. Each article reviewed includes a succinct overview of methodology and the results, followed by a discussion that puts the results into clinical context. All articles are selected and chapters written by primary care physicians who understand what is relevant to the intended audience for the book. Written by experts in the field, Top Articles Every Clinician Should Know provides readers with one source where information can be found about the most important articles published in the medical literature that informs the way clinicians practice primary care today.

Biological sex and gender have a tremendous impact on the efficacy and safety of pharmacological interventions in virtually every disease state. This book presents a comprehensive and up-to-date overview on how sex-specific information is guiding the diagnosis and treatment of diseases affecting men and women, as well as of disease states that disproportionally affects women. Experts in various fields discuss both preclinical and clinical research that is contributing to a better understanding of the impact of sex in the presentation, etiology, treatment, and disease outcomes. Also discussed are the challenges encountered in implementing this growing body of knowledge into practice, as well as possible avenues to recognize and reduce health disparities between men and women so that therapeutic interventions are tailored and improved.

There is a growing interest in unmet needs for the development of a new discipline in drug discovery and in university education on polypharmacology. However, there has not been a book with the comprehensive compilation of basic knowledge and advanced methodology that is needed. This book aims to meet the needs making Polypharmacology a new sub-discipline of Pharmacology, not only being a hot area of pharmacological research and education but also a new paradigm for drug discovery. It contains the contents covering the entire scope of Polypharmacology including systemic in-depth exposition of basic knowledge, novel concepts, innovative technologies, and translational and clinical applications by showcasing state-of-the-art strategies and step-by-step instructions of cutting-edge methods. The contents of this book targets broad readerships including scientists in pharmacology research and drug development, and university teachers and graduates in medical school or school of pharmacy.

This book allows readers to gain an in-depth understanding of the role of real-world data in pharmacoepidemiology, and highlights the strengths and limitations of the respective databases with regard to pharmacoepidemiological research. Over the past decade, the increasing use of real-world data in pharmacoepidemiological research has been accompanied by a growing recognition of the value of real-world evidence in clinical and regulatory decision-making. Electronic healthcare databases allow analyses of drug and vaccine utilization in routine care after approval, as well as investigations of their comparative effectiveness and safety. They are especially useful for the identification of rare risks and rare drug exposures over long periods of time, and as such sustainably extend the basis for drug safety research. This book provides an introduction to the role of real-world data in pharmacoepidemiological research and the main developments in the last 15years. It also offers a comprehensive overview of the general classification characteristics of databases, together with their strengths and limitations, and a detailed description of 21 individual databases, written by professionals who work with or maintain them.

The book addresses the divide between hyperglycemia and diabetes, newer glycemic concepts of “time in range”, molecular mechanisms behind insulin resistance, and an elegant outline of antidiabetes therapies designed to improve the pathophysiology of diabetes. Furthermore, it discusses biomarkers beyond low-density lipoprotein cholesterol (LDL-C) that may help improve cardiovascular outcomes and the huge unmet need despite valiant efforts to reduce LDL-C, modern therapeutic options to reduce LDL, elegant therapeutic approaches to address hypertension with and without diabetic kidney disease, optimal renin-angiotensin system blockade, and evaluation of patients with asymptomatic heart failure and coronary artery disease. It discusses the controversies of optimal renal assessment with difficulties in risk categorization, various rheumatic and immune dysfunctions with special reference to the COVID-19 pandemic, cancer association with diabetes and optimal screening methods, relationship of various diets with glycemic and metabolic control, diabetes in young, diabetes management in special situations such as kidney disease, liver disease and Ramadan, and finally risk factor management in diabetes with special reference to exercise and modern day antidiabetic therapeutics.

Addiction is increasingly being recognized as a major global public health issue, and an ever-growing number of medical specialties, psychological and social science training programs, and professional associations are including addiction as part of their training and continuing education curricula. The first edition of this book presented an overview of the spectrum of addiction-related problems across different cultures around the globe. Sharing the experience and wisdom of more than 260 leading experts in the field, and promoted by the International Society of Addiction Medicine, it compared and contrasted clinical practices in the field of addiction medicine on the basis of neurobiological similarities as well as epidemiological and socio-cultural differences.Building on the success of this inaugural edition, and taking into account the formal and informal comments received as well as an assessment of current need, this textbook presents general updated information while retaining the most requested sections of the first edition as demonstrated by the number of chapter downloads. It also provides a basic text for those preparing for the ISAM annual certification exam. Written by some 220 international experts, it is a valuable reference resource for anyone interested in medicine, psychology, nursing, and social science.

Two world-leading doctors reveal the true state of modern medicine and how doctors are letting their patients down. In Hippocrasy, rheumatologist and epidemiologist Rachelle Buchbinder and orthopaedic surgeon Ian Harris argue that the benefits of medical treatments are often wildly overstated and the harms understated. That overtreatment and overdiagnosis are rife. And the medical system is not fit for purpose: designed to deliver health care not health. This powerful exposé reveals the tests, drugs and treatments that provide little or no benefit for patients and the inherent problem of a medical system based on treating rather than preventing illness. The book also provides tips to empower patients – do I really need this treatment? What are the risks? Are there simpler, safer options? What happens if I do nothing? Plus solutions to help restructure how medicine is delivered to help doctors live up to their Hippocratic Oath.'One of the hardest things for a doctor to do... is nothing. This superb book explains how in medicine and surgery less is often not just more, it's closer to the oath we're all supposed to practise by.'— Norman Swan, award-winning producer and broadcaster of the Health Report and Coronacast'This eye-opening and enthralling book on the medical and moral hazards which beset the health profession is a must-read for patients and practitioners alike. From ‘tooth-fairy science'to medical disasters to the inflated business world of medicine, Hippocrasy is a profoundly thought-provoking and compelling work that challenges our perception of the practice of modern medicine.'— Kate McClymont AM, award-winning investigative journalist for the Sydney Morning Herald/The Age'Doctors are educated to do good. Yet, as the commercial imperatives of the medical industrial complex tighten their grip, doctors are becoming more and more worried that they are inflicting harm rather than creating benefit. This book is for them and, perhaps even more importantly, for their patients. The road to hell is paved with good intentions: read Hippocrasy and turn back.'— Iona Heath CBE, former President, The Royal College of General Practitioners'This brilliant book offers clear and compelling evidence that we're all at risk from too much medicine. Using the best of science, these two respected doctors blow the whistle on harmful healthcare. Buchbinder and Harris reveal how overdiagnosis, overtreatment and the medicalisation of normal life are major threats to human health. But this brilliant book also brings hope that we can wind back the harm and waste of unnecessary tests and treatments, and focus more on the great benefits medicine has to offer.'— Ray Moynihan, author of Too Much Medicine? and Selling Sickness, Assistant Professor, Bond University'About half of us in advantaged countries are now patients or ‘providers', or both, and a third of clinical interventions are futile at best. Seeking health is daunting and we could benefit from a guide. Rachelle Buchbinder and Ian Harris have provided such with this volume.'— Nortin M Hadler, author of The Last Well Person, The Citizen Patient and Worried Sick, Emeritus Professor of Medicine and Microbiology/Immunology, University of North Carolina'Throughout medical history, doctors have routinely ignored the fundamental Hippocratic injunction: ‘First, do no harm'. Most of their treatments produced lots of harms, with little or no benefit. This wonderful book punctures the hyped claims of modern medicine, showing that it is not nearly as scientific, safe, effective, and honest as it should be. Reading Hippocrasy is essential for doctors (to help make them become more cautious); but even more essential for patients (to help them become more self-protective).'— Allen Frances, author of Saving Normal, Professor and Chairman Emeritus of the Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine'A timely book from two leading doctors. The

This book is the collected images of Joanna Walitalo's first five years of woodburning artwork. Pyrography, the use of heat or fire to create an image, is an uncommon and sometimes under-appreciated media in the art world and commonly considered more of a craft. Joanna, like many other Midwest kids, was given a craft wood-burner when she was young, tried it once or twice, burnt herself and subsequently put it away. Many years later, she picked it up again, and this time stuck with it, pushing herself to create high detail, realistic artwork. Her professional background in biology, environmental policies and forestry led her to the idea of incorporating what she had learned about wood products into this unique art form, using her skills as an artist to spread the message of love, beauty and respect for the environment and our natural resources. The concept that all of her work is done on scrap wood builds an ethic of recycling into each piece of art. The name J. Walitalo was chosen because it covers both James and Joanna, a husband and wife team. The Walitalos enjoyed this hobby, where they could work together, James preparing and finishing the wood on which Joanna does her artwork.'It is very satisfying to work together to create something unique and special, especially when I can do it with my best friend,'Joanna reflects, referring to her husband James. No two pieces are the same because of the wood--each piece is a different size, species and grain. Sometimes it takes a while to find the right piece of wood for a particular image or to find the right image to fit a particular piece of wood. Each piece of art is done freehand, either drawing from life or from looking at reference photos.'Joanna's vision is honest and straightforward. Walitalo loves wood, and she thoughtfully integrates the natural design of the various wood grains and knots within her rendering. Under Joanna's experienced craftsmanship, scraps of basswood, pine, curly maple, etc. become her partners in the creative process. Walitalo's drawings are a wonderful example of the artist uniting her life's passions with her perfect expressive medium.'--Michael Volker, Assistant Professor (Lecturer III) Painting and Drawing, Central Michigan University'An extraordinary convergence of art, personal experience, growth and utilization of a renewable resource as a canvas. The narrative depicts and shares with the reader the thinking of the artist, her experiences in life and in her work. Joanna Walitalo has created a collection of artwork that utilizes pyrography to recognize people, nature and landscapes, and brought it to a single work that shares wood, nature and life.'--Andrew J. Storer, Dean, College of Forest Resources and Environmental Science, Michigan Tech University'Joanna Walitalo has an amazing capacity to recognize the personality of her subjects-both animal and human-and infuse that element into the finished piece. Using fine lines in either ink or pyrography, she brings forth the character of the time and place in her art. Her ethics of recycling wood that has either been rejected or has passed its time of usefulness as a product, lends heart and value to her work. This is an artist who loves, understands and values the natural world and can bring nature right into your home. Incredible!'--Barb Rogers, Manager, Wildlife Recovery Association, and retired art instructor Learn more at jwalitalowoodburning.com

This book provides an overview of the etiology of coronary artery disease and focuses on the main therapies and drug interventions currently available. It highlights drug pharmacology and therapeutic challenges, with a special emphasis on the underlying principles of available therapeutics and the on-going development of drugs for coronary artery disease.The book is divided into eight chapters, the first of which describes the classical mechanism of coronary artery disease and its clinical presentations. Chapter 2 lists the principles of and related evidence on the prevention and treatment of coronary artery disease. This includes diet and lifestyle management, and guidelines for the treatment of acute coronary syndrome and stable coronary artery disease. In turn, Chapter 3 describes revascularization treatments, covering percutaneous coronary interventions, coronary artery bypass grafts and thrombolysis. This chapter also addresses the main therapeutic challenges.The following chapters provide an overview of three major categories of coronary artery disease drugs, which target thrombosis (Chapter 4), lipid metabolism (Chapter 5), and hypertension (Chapter 6). Heart failure constitutes the major health burden in the late stage of coronary artery disease; accordingly, current heart failure therapeutics and related drug pharmacology are described in Chapter 7. In closing, Chapter 8 provides a summary of on-going clinical trials for coronary artery disease drug development and discusses a number of promising areas in which intensive research into new therapeutics is being pursued.Given its scope, the book will be of interest to clinicians, medical students and research scientists, as well as to pharmaceutical professionals who are seeking new therapies and drugs for coronary artery disease and related disorders.

Fighting the Opioid Epidemic: The Role of Providers and the Clinical Laboratory in Understanding Who Is Vulnerable covers the important aspects that are essential in fighting the opioid epidemic. This succinct reference highlights how the toxicology laboratory can play a vital role in fighting the opioid epidemic by implementing a robust system for drugs of abuse testing as well as drug testing in pain management patients. It targets health care professionals in a technical manner, discussing polymorphisms of important genes that may be associated with increased vulnerability of alcohol and drug addiction to an individual. - Covers all important aspects of opioid abuse, including genetic and environmental factors - Discusses pharmacology, toxicology and the pharmacogenomics related to opioid metabolism - Presents genetic and environmental factors associated with those vulnerable to opioid addiction, as well as the pitfalls of drug testing in pain management

Fundamentals of Analytical Toxicology is an integrated introduction to the analysis of drugs, poisons, and other foreign compounds in biological and related specimens. Assuming only basic knowledge of analytical chemistry, this invaluable guide helps trainee analytical toxicologists understand the principles and practical skills involved in detecting, identifying, and measuring a broad range of compounds in various biological samples. Clear, easy-to-read chapters provide detailed information on topics including sample collection and preparation, spectrophotometric and luminescence techniques, liquid and gas-liquid chromatography, and mass spectrometry including hyphenated techniques. This new edition contains thoroughly revised content that reflects contemporary practices and advances in analytical methods. Expanding the scope of the 1995 World Health Organization (WHO) basic analytical toxicology manual, the text includes coverage of separation science, essential pharmacokinetics, xenobiotic absorption, distribution and metabolism, clinical toxicological and substance misuse testing, therapeutic drug monitoring, trace elements and toxic metals analysis, and importantly the clinical interpretation of analytical results. Written by a prominent team of experienced practitioners, this volume: Focuses on analytical, statistical, and pharmacokinetic principles Describes basic methodology, including colour tests and immunoassay and enzyme-based assays Outlines laboratory operations, such as method validation, quality assessment, staff training, and laboratory accreditation Follows IUPAC nomenclature for chemical names and recommended International Non-proprietary Name (rINN) for drugs and pesticides Includes discussion of'designer drugs'(novel pharmaceutical substances NPS) Fundamentals of Analytical Toxicology: Clinical and Forensic, 2nd Edition is an indispensable resource for advanced students and trainee analytical toxicologists across disciplines, such as clinical science, analytical chemistry, forensic science, pathology, applied biology, food safety, and pharmaceutical and pesticide development.

This classic, field-defining textbook, now in its sixth edition, provides the most comprehensive guidance available for anyone needing up-to-date information in pharmacoepidemiology. This edition has been fully revised and updated throughout and continues to provide a rounded view on all perspectives from academia, industry and regulatory bodies, addressing data sources, applications and methodologies with great clarity.

Biotin and Other Interferences in Immunoassays: A Concise Guide is aimed at clinical laboratory scientists, medical technologists and pathologists who are often the first individuals contacted by a clinician when a laboratory test result does not correlate with clinical presentation. Research scientists working in diagnostics companies will also find this information essential. Sources of errors in non-immunoassay based methods used in clinical chemistry and toxicology laboratory are also discussed so readers can get all important information from one concise guide. This succinct, user-friendly reference provides the necessary information to address high levels of biotin in clinical laboratory results. - Discusses issues of biotin interferences and ways to avoid them for accurate clinical laboratory results - Provides sources of errors in non-immunoassay based methods used in clinical chemistry and toxicology laboratories - Highlights how to handle specimens in the lab and how to eliminate the effect of biotin in precious samples

Critical Issues in Alcohol and Drugs of Abuse Testing, Second Edition, addresses the general principles and technological advances for measuring drugs and alcohol, along with the pitfalls of drugs of abuse testing. Many designer drugs, for example, are not routinely tested in drugs of abuse panels and may go undetected in a drug test. This updated edition is a must-have for clinical pathologists, toxicologists, clinicians, and medical review officers and regulators, bridging the gap between technical and clinical information. Topics of note include the monitoring of pain management drugs, bath salts, spices (synthetic marijuana), designer drugs and date rape drugs, and more. - Serves as a ready resource of information for alcohol and drug testing - Ideal resource for making decisions related to the monitoring and interpretation of results - Includes concise content for clinical laboratory scientists, toxicologists and clinicians

TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIAL INFECTIONS TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIAL INFECTIONS SEVENTH EDITION Complete coverage of every aspect of tuberculosis and related mycobacterial infections “Tuberculosis appears to be as old as humanity itself.” Despite many advancements since the 1882 identification of Mycobacterium tuberculosis as the causative agent of tuberculosis, it remains one of the top 10 causes of death worldwide and threatens the effectiveness of our therapeutic arsenal. In 2015, 1.8 million people died of tuberculosis and almost half a million new cases of multidrug-resistant tuberculosis were diagnosed. For Tuberculosis and Nontuberculous Mycobacterial Infections, Dr. Schlossberg assembled an international team of experts to write about nearly every facet of the prevention, diagnosis, and treatment of tuberculosis and nontuberculous mycobacterial infections. In addition to presenting the latest clinical data, epidemiological findings, and policy and strategy recommendations of the World Health Organization, four new chapters cover topics of critical importance: The role of therapeutic drug monitoring in mycobacterial infections The public health issues of refugees and migrants, and their exposure and transmission of tuberculosis resulting from humanitarian crises Diabetes mellitus as a significant risk factor for tuberculosis The increased risk of tuberculosis reactivation in people taking tumor necrosis factor alpha inhibitors and other biopharmaceuticals Other chapters provide detailed information on the clinical, public health, and policy aspects of tracking and treating tuberculosis, including: The many presentations of tuberculosis, from pulmonary to ocular and cardiovascular to urogenital The complications that tuberculosis and antituberculosis therapy cause to the hematologic and endocrine systems Tuberculosis during pregnancy and in infants and children Treatment of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis Development of new vaccines Nontuberculous infections caused by mycobacteria found throughout our environment The seventh edition of Tuberculosis and Nontuberculous Mycobacterial Infections is an essential resource for anyone working to prevent and treat tuberculosis and associated infections, from infectious disease specialists and pulmonologists to scientists, policymakers, and epidemiologists. A truly modern book that offers students, practitioners, and all readers the chance for a full immersion into the science of tuberculosis.” —MARIO RAVIGLIONE, MD, Global TB Programme, World Health Organization “It's difficult to improve on an already excellent book but Dr. Schlossberg and colleagues have done it again!” —BURKE A. CUNHA, MD, MACP, Infectious Disease Division, Winthrop-University Hospital “This comprehensive book remains the most popular reference among physicians treating tuberculosis.” —LEONID HEIFETS, MD, National Jewish Hospital (from a previous edition) “This book meets a demand for timely information…constitutes a ready and useful reference for general internists and primary care physicians.” —ANNALS OF INTERNAL MEDICINE (from a previous edition)If you are looking for online access to the latest clinical microbiology content, please visit www.wiley.com/learn/clinmicronow.

Alcohol, Drugs, Genes and the Clinical Laboratory provides an overview and quick reference to genetic relationships and clinical laboratory information related to the serious public health issue of alcohol and drug abuse. Written in a clear and concise manner, this book discusses the necessary information for health and safety professionals working in public health to learn about complex issues quickly to better help their patients, employees, and others affected by alcohol and drug abuse. Alcohol, Drugs, Genes and the Clinical Laboratory covers the important aspects of drugs and alcohol abuse including genetic aspects along with laboratory methods for analysis of alcohol and abused drugs with emphasis on false positive test results. The book is helpful to healthcare professionals, such as pathologists who oversee alcohol and drug testing, emergency room physicians, family practice physicians who are first healthcare professionals who identify patients susceptible to drug and alcohol abuse, and psychiatrists involved with drug and alcohol rehabilitation programs. It will also be useful to safety professionals who have to assess individuals for workplace responsibilities, ranging from police and recruitment to occupational safety and occupational medicine and public health officials. - Features accessible language for healthcare and safety professionals who are not experts in laboratory procedures - Provides examples from clinical and everyday situations - Explains how to interpret laboratory results and the latest genetic factors regarding drug and alcohol abuse

This practical, easy-to-use guide, named to Doody's Core Titles 2013, addresses interference issues in all laboratory tests, including patient epigenetics, process of specimen collection, enzymes, biomarkers. Clinicians and laboratory scientists can therefore rely on one reference which speaks to both their needs of accurate specimen analysis and optimal patient care. Erroneous hospital and pathology laboratory results can be confusing and problematic, especially in acute care situations. While some factors creating interference, can be identified in the laboratory, detecting many others is often dependent on clinical details unavailable to the laboratory scientists or pathologists. Therefore, clinicians must become proficient in identifying such erroneous reports, and working with pathologists and laboratory scientists so that they can understand the source of such interferences, correct the results, and then decide what course of action must be followed for proper patient management. - Named to Doody's Core Titles 2013, a collection development tool for health sciences libraries of all sizes, by Doody Enterprises - Practical information for both clinicians and laboratory scientists, presented in the form of tables and charts for easy reference - Focus on range and sources of interferences rather than details of toxicologic mechanisms which are well covered in toxicology textbooks - Covers interferences across endocrine, oncology, hematology, immunohistochemistry, immunology, serology, microbiology, and molecular testing

Hepatitis viruses research started more than fifty years ago. The names of hepatitis A and hepatitis B were introduced in 1947 when it became clear that there were two types of hepatitis that were transmitted either enterically or parenterally. It became apparent in the 1970's that there were additional hepatitis viruses distinct from hepatitis A and hepatitis B, and thus, the term non-A, non-B hepatitis was introduced. The non-A, non-B hepatitis was further divided into post-transfusion non-A, non-B hepatitis and enterically-transmitted non-A, non-B hepatitis in the 1980's. By the end of the 1980's, both post-transfusion non-A, non-B virus and enterically-transmitted non-A, non-B virus had been identified and renamed hepatitis C virus and hepatitis E virus, respectively. Hepatitis delta antigen was first recognized as an antigen associated with hepatitis B virus infection in the 1970's. In the early 1980's, a virus was isolated and named hepatitis delta virus. These five different hepatitis viruses have distinct replication pathways and are major health concerns. They have become an important topic for teaching to graduate-level and medical students. Hepatitis Viruses provides a comprehensive, up-to-date review of these viruses to readers. Each chapter is written by one of the top researchers in the field, and topics include: the epidemiology and the natural history of infection of these viruses, the molecular biology and the replication cycle of individual hepatitis viruses, host-virus interactions and the pathogenesis of hepatitis viruses, the immunology of hepatitis viruses, the relationship between hepatitis viruses and hepatocellular carcinoma, the viral vaccines and antiviral drugs. This book can serve as a supplemental reading material to graduate students and medical students, and to any researcher who would like to learn more about hepatitis viruses.

The tools for detecting false positives, false negatives, and interference in interactions when testing and monitoring therapeutic drug use For physicians monitoring a patient's progress, efficacy of treatment is often linked to a patient's response to medication. Determining whether a patient is taking the prescribed amount, the drug or dosage is effective, or the prescribed medication is interacting with other drugs can be determined through drug testing. Written as a guide for toxicologists, chemists, and health professionals involved in patient care, Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring provides an up-to-date introduction to the tests and methodologies used in a toxicology lab as well as the sources of testing error that can lead to false positives, false negatives, and unreliable conclusions of drug abuse or under use. Covering a host of common therapeutic drugs as well as specific types of interference in immunoassays used in drug testing, the book details a number of possible testing scenarios and problems as well as solutions: False positive results in immunoassays for drugs in abuse testing Interferences in immunoassays used for monitoring anticonvulsants, tricyclic antidepressants, and digoxin False positive alcohol tests using breath analyzers and automated analyzers When a toxicology report is negative in a suspected overdose patient: the world of designer drugs Effects of drug-herb interactions on therapeutic drug monitoring Pharmacogenomics and the general principles of genetic analysis Approaches for eliminating interference/discordant specimen in therapeutic drug monitoring and drugs in abuse testing What to do in case there is no readily available method for testing Complete with easy-to-read tables and flowcharts, this book helps toxicologists, clinical chemists, clinical pathologists, and forensic pathologists develop accurate, unbiased drug monitoring and toxicology reports. Health care professionals involved in patient care, especially of critically ill patients, will find this guide indispensable in making sure lab tests are reliable enough to provide high-quality care. An indispensable handbook to the entire suite of toxicology lab tests, as well as all the possible sources of testing error, Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring offers clear remedies for eliminating and preventing testing error.

This book provides a broad reference covering important drugs of abuse including amphetamines, opiates, and steroids. It also covers psychoactive plants such as caffeine, peyote, and psilocybin. It provides chemical structures, analytical methods, clinical features, and treatments of these drugs of abuse, serving as a highly useful, in-depth supplement to a general medical toxicology book. The style allows for the easy application of the contents to searchable databases and other electronic products, making this an essential resource for practitioners in medical toxicology, industrial hygiene, occupational medicine, pharmaceuticals, environmental organizations, pathology, and related fields.

Chronic hepatitis C is a major worldwide health problem affecting more than 170 million people. Chronic infections lead to cirrhosis and liver failure or hepatocellular cancer in many instances. This volume includes comprehensive reviews that cover much of the vast literature that has appeared since the identification of the hepatitis C virus RNA genome. It will be an invaluable collection for anyone wanting an up-to-date picture of HCV transmission, molecular virology, immune response, cellular/molecular pathogenesis, and possible avenues for developing effective new therapeutics and vaccines.

The objective of this volume is to give an overview of the present state of the art of pediatric clinical pharmacology including developmental physiology, pediatric-specific pathology, special tools and methods for development of drugs for children (assessment of efficacy, toxicity, long-term safety etc.) as well as regulatory and ethical knowledge and skills. In the future, structural and educational changes have to lead back to a closer cooperation and interaction of pediatrics with (clinical) pharmacology and pharmacy.